52 proof-checking-postdoc-computer-science-logic Fellowship positions at University of Birmingham in United Kingdom
Sort by
Refine Your Search
-
bioinformatics. The successful candidate will join a team with a strong track record in developing computational tools and informatics infrastructure for metabolomics applications in toxicology, systems biology
-
Job Description Position Details Department of Applied Health Sciences, School of Health Sciences, College of Medicine and Health Location: University of Birmingham, Edgbaston, Birmingham UK Full
-
Job Description Position Details School of Chemistry Location: University of Birmingham, Edgbaston, Birmingham UK Full time starting salary is normally in the range £36,130 to £45,413 with potential
-
Job Description Position Details School of Chemistry Location: University of Birmingham, Edgbaston, Birmingham UK Full time starting salary is normally in the range £36,130 to £45,413 with potential
-
Job Description Position Details School of Engineering Location: University of Birmingham, Edgbaston, Birmingham UK Full time starting salary is normally in the range £36,130 to £45,413 with
-
Summary Work within the PRE-EMPT programme grant and its team of co-applicants Operate within area of specialism (implementation science/behaviour change/maternal health) Analyse and interpret data and
-
Job Description Position Details School of Geography, Earth and Environmental Sciences Location: University of Birmingham, Edgbaston, Birmingham UK Full time starting salary is normally in the range
-
Job Description Position Details Department of Nursing and Midwifery, School of Health Sciences, College of Medicine and Health Location: University of Birmingham, Edgbaston, Birmingham UK Full time
-
://www.cerebranetwork.com/ In your application please include a cover letter stating how you match the person specification. Role Summary Work within specified industry grant and charity funded project Oversee and contribute
-
(HPB). The medical oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor